Development and function of tissue-resident memory B cells

Chen, Changfeng; Laidlaw, Brian J.

doi:10.1016/bs.ai.2022.08.001

Cited by 7 publications

(5 citation statements)

References 198 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Autoantibodies are produced by B cells, which are self-reacting, thereby triggering an inflammatory response. In terms of health benefits, B cells produce protective anti-bodies [93]. In SLE, autoantibodies are produced, which are involved in triggering an inflammatory response via multiple mechanisms, including the induction of cytokine and interferon production by innate immune cells [94].…”

Section: B Cell Targeted Treatmentmentioning

confidence: 99%

Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus

Athanassiou

2023

Life

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE), the prototype of systemic autoimmune diseases is characterized by extreme heterogeneity with a variable clinical course. Renal involvement may be observed and affects the outcome. Hydroxychloroquine should be administered to every lupus patient irrespective of organ involvement. Conventional immunosuppressive therapy includes corticosteroids, methotrexate, cyclophosphamide, mycophenolate mofetil, azathioprine, cyclosporine and tacrolimus. However, despite conventional immunosuppressive treatment, flares occur and broad immunosuppression is accompanied by multiple side effects. Flare occurrence, target organ involvement, side effects of broad immunosuppression and increased knowledge of the pathogenetic mechanisms involved in SLE pathogenesis as well as the availability of biologic agents has led to the application of biologic agents in SLE management. Biologic agents targeting various pathogenetic paths have been applied. B cell targeting agents have been used successfully. Belimumab, a B cell targeting agent, has been approved for the treatment of SLE. Rituximab, an anti-CD20 targeting agent is also used in SLE. Anifrolumab, an interferon I receptor-targeting agent has beneficial effects on SLE. In conclusion, biologic treatment is applied in SLE and should be further evaluated with the aim of a good treatment response and a significant improvement in quality of life.

show abstract

Section: B Cell Targeted Treatmentmentioning

confidence: 99%

Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus

Athanassiou

2023

Life

View full text Add to dashboard Cite

show abstract

“…Following primary infection with influenza virus, clusters of PCs that associate with iBALT-like structures develop and persist in the lung ( MacLean et al, 2022 ; Oh et al, 2021 ). Shortly after rechallenge, new PCs develop in these sites ( Allie and Randall, 2020 ; Chen and Laidlaw, 2022 ; Lee and Oh, 2022 ; Reusch and Angeletti, 2023 ), forming large aggregates that retain their confined distribution (referred in this study to as “clustered” PCs) ( MacLean et al, 2022 ) ( Fig. S1 A ).…”

Section: Resultsmentioning

confidence: 99%

Regulation of pulmonary plasma cell responses during secondary infection with influenza virus

MacLean,

Bonifacio,

Oram

et al. 2024

Journal of Experimental Medicine

View full text Add to dashboard Cite

During secondary infection with influenza virus, plasma cells (PCs) develop within the lung, providing a local source of antibodies. However, the site and mechanisms that regulate this process are poorly defined. Here, we show that while circulating memory B cells entered the lung during rechallenge and were activated within inducible bronchus-associated lymphoid tissues (iBALTs), resident memory B (BRM) cells responded earlier, and their activation occurred in a different niche: directly near infected alveoli. This process required NK cells but was largely independent of CD4 and CD8 T cells. Innate stimuli induced by virus-like particles containing ssRNA triggered BRM cell differentiation in the absence of cognate antigen, suggesting a low threshold of activation. In contrast, expansion of PCs in iBALTs took longer to develop and was critically dependent on CD4 T cells. Our work demonstrates that spatially distinct mechanisms evolved to support pulmonary secondary PC responses, and it reveals a specialized function for BRM cells as guardians of the alveoli.

show abstract

“…Tissue-resident memory B cells in humans and mice have been found in non-lymphoid tissues that are phenotypically and functionally distinct from their classical lymphoid-associated counterparts (145)(146)(147). Tissue-resident memory B cells (BRM) perform protective functions in peripheral tissues dependent on their ability to engage antigen at the site of infection, secrete cytokines, and differentiate into plasma cells (147).…”

Section: B Cell Memory Diversity and Tissue Resident B Cell Memorymentioning

confidence: 99%

NF-kB’s contribution to B cell fate decisions

2023

View full text Add to dashboard Cite

NF-κB signaling is essential to an effective innate and adaptive immune response. Many immune-specific functional and developmental outcomes depend in large on NF-κB. The formidable task of sorting out the mechanisms behind the regulation and outcome of NF-κB signaling remains an important area of immunology research. Here we briefly discuss the role of NF-κB in regulating cell fate decisions at various times in the path of B cell development, activation, and the generation of long-term humoral immunity.

show abstract

Development and function of tissue-resident memory B cells

Cited by 7 publications

References 198 publications

Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus

Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus

Regulation of pulmonary plasma cell responses during secondary infection with influenza virus

NF-kB’s contribution to B cell fate decisions

Contact Info

Product

Resources

About